- Home
- ATNF
as 11-22-2024 4:00pm EST
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 2.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 184.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.16 - $17.75 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 54.15% |
Latest 180 Life Sciences Corp. News
ATNF Breaking Stock News: Dive into ATNF Ticker-Specific Updates for Smart Investing
ACCESSWIRE
23 days ago
180 Life Sciences Corp. Retains Senior Technology Consultant and Commences Gaming Technology Platform Integration
ACCESSWIRE
25 days ago
180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors
GlobeNewswire
a month ago
Elray Resources Announces Strategic Sale of Crypto iGaming Technology
GuruFocus.com
a month ago
180 Life Sciences' Brave Decision To Switch to the iGaming Industry
ACCESSWIRE
a month ago
180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform
ACCESSWIRE
a month ago
180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector
ACCESSWIRE
2 months ago
180 Life Sciences Corp. - Corporate Updates
GlobeNewswire
2 months ago
180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer
Compare ATNF vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATNF 180 Life Sciences Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.